In breast cancer, EGFR and HER2 are frequently over-expressed and are associated with aggressive clinical behavior and poor outcome [31,32]; however, the outcome for patients with these highly aggressive tumors has markedly improved with the development of anti-HER2 therapies. Here, EGFR is linked to breast carcinoma.